Your position:
m.limatoxi.com
>>
EN
>>
EN
>>
Formulation
>>
Novartis Acquires FDA Priority Review Voucher from bluebird bio for $103 Million
>> article
Novartis Acquires FDA Priority Review Voucher from bluebird bio for $103 Million
Editor:xuezhe Clicks:
0
Date:2023-11-3 15:39:00
Keyword:
FDA
Healthoo Information:
Novartis Acquires FDA Priority Review Voucher from bluebird bio for $103 Million
UserLogin
UserName：
Password：
The non-formal user may read the summary, the formal user can read the whole article。
please at once register the user of Heatlhoo.com
After registration, we will provide the sample reports and the more comprehensive consulting services for you.
UserName
Contact:
Title:
Mr.
Ms.
Password
Repeat password:
Mobile
Email
Verification code:
Company Name
E-mail:xuezhe@healthoo.com
Tel.:86-10-68032463
Our services:
China Im\Ex data service
Service fees of Chinese Vision
Our service items
Online information introduction
Monthly information
Relative Information
Multiple product indications withdrawn, FDA accelerated Approval How t...
Tronsound long-acting IL-36R antibody obtained FDA clinical IND
Tronsound long-acting IL-36R antibody obtained FDA clinical IND
2022 FDA approval of new drug transcript
The first in the world! Huadong Pharmaceuticals new FRα target ADC was...
FDA Success Stories CDE Recommendations: How MIDD Accelerates Drug Dis...
The worlds first Upadatinib extended-release tablets approved by FDA f...
Sodium thiosulfate has been approved by the FDA to reduce hearing loss...
FDA approves ibrutinib for chronic graft-versus-host disease in childr...
FDA Issues Drug Statement, Mercks Hypoglycemic Drug Sitagliptin Detect...
Address: Suite 13F,NO2 Building, FuXing International, TianHua North Street, Yizhuang, Daxing District, Beijing, P.R. China
Tel:+86-10-68032463
map
